PMC9810787_01
(A) Dynamic changes in blood cell count during ven + flu treatment. (B) Treatment process of the patient. CR, complete remission; PR, partial remission; NR, non-remission; HA, homoharringtonine and cytarabine; Aza, 5-azacitidine; Ara, cytarabine; Ima, imatinib; Ven, venetoclax; Flu, flumatinib; BM, bone marrow blast cell. BCR::ABL1, the presence of BCR::ABL1 fusion gene calculated with standard materials was normalized with respect to the number of ABL1 transcripts and expressed as copy numbers per 1 x 104 copies of abl.
CCR3-11-e6688-g001.jpg
PMC9810787_01_CCR3-11-e6688-g001.jpg
ccr36688-fig-0001
No serious adverse events occurred during the treatment, although hematological toxicity was observed (Figure 1A). In the subsequent consolidation therapy, the flumatinib plus venetoclax regimen was administered regularly 3 times (Figure 1B).